The 340B drug discount program may move under the purview of CMS, according to a leaked HHS restructuring document reviewed ...

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign ...

Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

Roche is stopping patients on the low dose of its experimental Huntington’s drug tominersen, and will be transitioning them ...

Sanofi is teaming up with a private biotech in Delaware on a pair of bispecific antibodies for autoimmune and inflammatory ...

UnitedHealth Group reported disappointing first-quarter earnings and cut its financial guidance, hit by high costs in its ...

The Dutch government is committing €1.3 billion ($1.5 billion) to support biotech as part of a broader raft of measures ...

Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series ...

Walgreens to go private via Sycamore Partners deal at $11.45/share after talks began in Feb 2024. Deal impacted by $595M Everly Health settlement. Expected to close Q4 2024.

Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b ...

US brand-name drugs use foreign ingredients, with Europe supplying 43% of APIs, as Trump administration considers 25% tariffs ...